Sulfonamide Global Market Report 2025

The sulfonamide market size has grown strongly in recent years. It will grow from $2.72 billion in 2024 to $2.91 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the increasing prevalence of bacterial infections, growing availability of generic sulfonamide drugs, rising cost-effective treatment options, expanded use in veterinary medicine, and the expanding pharmaceutical manufacturing capacity.

The sulfonamide market size is expected to see strong growth in the next few years. It will grow to $3.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising demand for combination therapies, increasing focus on antimicrobial resistance management, expansion of healthcare access in developing regions, growing applications in agriculture and animal husbandry, and supportive regulatory approvals for sulfonamide formulations. Major trends in the forecast period include advancements in drug delivery technologies, innovations in sulfonamide derivatives, development of targeted antibacterial therapies, ongoing research and development in antimicrobial agents, and integration of artificial intelligence in drug discovery.

The growing prevalence of skin infections is expected to drive the expansion of the sulfonamide market. Skin infections, caused by bacteria, viruses, fungi, or parasites invading the skin, lead to symptoms such as redness, swelling, pain, itching, or pus formation. The rise in skin infections is largely due to the increasing presence of antibiotic-resistant bacteria, making common infections more difficult to treat and more likely to spread. Sulfonamides are effective in treating skin infections by inhibiting bacterial growth and disrupting folic acid synthesis, making them effective against various susceptible bacteria. For example, in February 2025, the American Academy of Dermatology, a U.S.-based nonprofit organization, reported that approximately 50 million Americans suffer from acne each year, making it the most common skin condition in the country. As a result, the increasing prevalence of skin infections is fueling the growth of the sulfonamide market.

Companies in the sulfonamide market are focusing on developing innovative therapies, such as those for primary periodic paralysis (PPP), to expand the therapeutic applications of sulfonamide-based drugs and address unmet needs in rare neuromuscular disorders. PPP therapies are designed to manage a group of rare, inherited neuromuscular disorders that cause episodes of muscle weakness or paralysis triggered by changes in blood potassium levels. For example, in May 2024, Cycle Pharmaceuticals Limited, a U.K.-based pharmaceutical company, introduced ORMALVITM (dichlorphenamide) as a therapy option for patients with hypokalemic periodic paralysis (HypoPP), hyperkalemic periodic paralysis (HyperPP), and similar conditions. This FDA-approved therapy provides a specialized treatment for these genetic disorders, characterized by muscle weakness or paralysis linked to fluctuations in potassium levels. A notable feature of this launch is Cycle’s patient-centric approach, which focuses on improving accessibility and adherence through tailored support services.

In June 2023, Shionogi & Company Limited, a Japan-based pharmaceutical company, merged with Qpex Biopharma Inc. to accelerate antibiotic research and development, addressing the growing issue of antimicrobial resistance (AMR). This merger allows Shionogi to enhance its expertise in antibiotic research and AMR by combining its strengths with Qpex Biopharma's innovative compounds and networks, speeding up the development of vital pharmaceuticals. Qpex Biopharma Inc. is a U.S.-based company focused on creating novel anti-infective therapies, particularly those targeting drug-resistant infections.

Major players in the sulfonamide market are Abbott Laboratories, Novartis AG, Teva Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Lupin Limited, Bimeda Holdings PLC, Fera Science Limited, Virchow Laboratories Limited, Hebei Veyong Bio-Chemical Co. Ltd., Interchemie Werken De Adelaar B.V., AdvaCare Pharma, Manus Aktteva Biopharma LLP, Suleshvari Pharma, Shree Vardayini Chemical Industries Private Limited, VetOne, Zydus Cadila Healthcare Limited, Mission Pharmacal Company, Allegis Pharmaceuticals LLC.

North America was the largest region in the sulfonamide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sulfonamide report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sulfonamide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sulfonamide market consists of sales of sulfamethoxazole, sulfadiazine, furosemide, and thiazide diuretics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Sulfonamide refers to a group of synthetic antimicrobial agents containing the sulfonamide group, used to treat bacterial infections by inhibiting folic acid synthesis in microbes. These compounds were among the earliest antibiotics developed and remain in use today as part of combination therapies for various infections.

The main product types of sulfonamide include oral sulfonamides, topical sulfonamides, and injectable sulfonamides. Oral sulfonamides are antibiotics that contain the sulfonamide group (-SO₂NH₂) in their chemical structure. The key chemical structures include sulfanilamide, sulfacetamide, and sulfamethoxazole. Applications include antibacterial, antifungal, antiviral, diuretics, antidiabetic, and others, and they are used by various end users such as hospitals, clinics, research laboratories, and others.

The sulfonamide market research report is one of a series of new reports that provides sulfonamide market statistics, including the sulfonamide industry global market size, regional shares, competitors with the sulfonamide market share, detailed sulfonamide market segments, market trends, and opportunities, and any further data you may need to thrive in the sulfonamide industry. This sulfonamide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.